A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
PRIMARY OBJECTIVE:
I. To estimate the overall response rates of olaparib in subjects with recurrent/progressive
IDH1/2-mutant solid tumors, who will be recruited to 3 cohorts: a. glioma, b.
cholangiocarcinoma, c. other solid malignant tumors.
SECONDARY OBJECTIVES:
I. To estimate the distribution of progression free survival (PFS) of olaparib in adults with
recurrent/progressive IDH1/2-mutant glioma and cholangiocarcinoma.
II. To estimate the overall survival (OS) in adults with recurrent/progressive IDH1/2- mutant
glioma and cholangiocarcinoma.
III. To determine the duration of response in adults with recurrent/progressive IDH1/2-mutant
glioma, cholangiocarcinoma or other solid malignant tumors.
IV. To confirm the safety and tolerability of olaparib monotherapy.
EXPLORATORY OBJECTIVES:
I. To describe 2HG concentration in plasma by mass spectrometry at baseline and at specific
timepoints and correlate with treatment response.
II. To describe 2HG levels in tumor biopsies from prior to the beginning of treatment and at
specific timepoints and correlate with treatment response.
III. To evaluate in tumor biopsies and in liquid biopsies performed at baseline and at
specific timepoints if co-occurring alterations detected via multiplexed immunofluorescence,
mass cytometry (CyTOF)-imaging mass cytometry (IMC), ribonucleic acid (RNA) sequencing and/or
deoxyribonucleic acid (DNA) sequencing can be associated with differential levels of 2HG
production, treatment response and resistance.
OUTLINE:
Patients receive olaparib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28
days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Powered by
SC CTSI